Orthopedic device maker Biomet said Monday FQ4 earnings fell more than 50% to $0.17/share ($41.5 million), from $0.41 ($100.4 million) a year earlier. Excluding special items and compensation expenses EPS was $0.39 cents a share on net sales of $549.4 million, up from $539 million a year ago. Both earnings and revenue fell short of analyst estimates, which were calling for EPS of $0.49 on revenue of $573 million. Sales of reconstructive devices fell 8%, fixation sales dropped 22%, and spinal products fell 10%, while hip sales gained 7% and extremity sales were up 13%. In June, the company agreed to be acquired by a private equity consortium of Blackstone, KKR, TPG and Goldman Sachs' private equity arm.
Sources: Press release, MarketWatch, Bloomberg,
Commentary: Biomet: I Would Cheer If The Deal Fell Apart • Biomet Buyout Offer Was Way Too Low
Stocks/ETFs to watch: Biomet Inc. (Pending:BMET), Blackstone Group LP (NYSE:BX), Goldman Sachs Group Inc. (NYSE:GS). Competitors: Medtronic Inc. (NYSE:MDT), ArthroCare Corp. (NASDAQ:ARTC), Johnson & Johnson (NYSE:JNJ), Orthofix International N.V. (NASDAQ:OFIX)
Conference call transcript: Biomet F1Q07
Seeking Alpha's news briefs are combined into a pre-market summary called Wall Street Breakfast. Get Wall Street Breakfast by email -- it's free and takes only seconds to sign up.